RNS Number : 3101K
Kromek Group PLC
28 May 2025

28 May 2025

Kromek Group plc
("Kromek" or the "Group")

New Nuclear Security Orders
Two orders to supply D3 series detectors to a European and a US customer

Kromek Group plc (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, is pleased to announce that it has received two orders to supply its D3 series of detectors for use by a European and a US customer.

The orders, valued together at approximately $900k, are for immediate delivery. The European customer is dedicated to fostering civilian science and technology partnerships aimed at mitigating global CBRN security risks and advancing non-proliferation efforts. The US customer is a leading supplier of integrated products working in the defence and security sector with a history of implementing innovative security solutions.

The customers will receive the Group's D3 series of detectors to enhance their capabilities in the timely detection of radiation levels, as well as to facilitate data collection and processing and real-time data transmission. This will enable better informed decision-making and rapid responses to potential threats to national safety and security.

Arnab Basu, Chief Executive Officer of Kromek, said:*"We are pleased to announce the receipt of these new orders that underscore our continued commitment to providing advanced detection solutions for emergency response services. Our proprietary technology is instrumental in mitigating radiological and nuclear threats through rapid, reliable detection and real-time data transmission capabilities.*

"In an environment marked by ongoing geopolitical uncertainty, demand for our solutions continues to grow, highlighting Kromek's vital role in supporting global safety and security efforts. These orders reflect the increasing trust in our innovative technologies and further solidify Kromek's position as a leading provider in the critical security market."

For further information, please contact:

Kromek Group plc	
Arnab Basu, CEO	+44 (0)1740 626 060
Paul Farquhar, CFO	
Cavendish Capital Markets Limited (Nominated Adviser and Broker)	
Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance	+44 (0)20 7220 0500
Tim Redfern - ECM	
Michael Johnson - Sales	
Gracechurch Group (Financial PR)	
Harry Chathli/Claire Norbury/Henry Gamble	+44 (0)20 4582 3500

Kromek Group plc

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDFFFVIEVIDFIE